Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Silence Therapeutics, MiReven Ink Collaboration - Quick Facts

8/22/2012 2:55 AM ET

Silence Therapeutics Plc (SLN.L) said it has signed an agreement with MiReven Pty Ltd. to assess the delivery potential of Silence Therapeutics' proprietary delivery systems with MiReven's novel microRNA-based therapeutics. MiReven, an Australian-based microRNA company, is commercialising discoveries from the Western Australian Institute for Medical Research on the anti-cancer potential of miR-7.

As per the terms of the agreement, Silence Therapeutics will formulate a miR-7 mimetic with its proprietary AtuPLEX, DACC and DBTC delivery systems in order to assess miR-7 in various cancer models. The company will undertake in vitro and in vivo studies of the formulated miR-7. Silence Therapeutics is being paid an undisclosed fee for the collaboration.

Click here to receive FREE breaking news email alerts for Silence Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Bank of Japan on Wednesday decided to keep its ultra-loose monetary policy unchanged, as expected, suggesting that the bank is moving cautiously amid concerns over the recent turmoil in the bond market. The policy board said the bank will conduct money market operations so that the monetary base will increase at an annual pace of about JPY 60-70 trillion. Confidence among Australian consumers declined sharply in May to its lowest level since August 2012, driven largely by negative responses to the Federal Budget, a survey by Westpac and Melbourne Institute showed Wednesday. The index of consumer sentiment fell 7 percent in May to 97.6 from 104.9 in April. This is the lowest reading since August 2012. Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.